HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.

Luciana de Moura Leite Marcelle Goldner Cesca Monique Celeste TavaresDebora Maciel SantanaErick Figueiredo SaldanhaPaula Tavares GuimarãesDaniella Dias Silva Sá Maria Fernanda Evangelista Simões Rafael Lima VianaFrancisca Giselle RochaSimone Klog LooseSinara Figueiredo SilvaRafaela Pirolli Camilla Albina Zanco FogassaBruna Raphaeli Silva MattosFernando Augusto Batista Campos Solange Moraes Sanches Vladmir Cláudio Cordeiro de Lima Noam Falbel Pondé

Published in: Breast cancer research and treatment (2021)

Our data does not support HER2-low as a biologically distinct BC subtype, with no prognostic value on survival outcomes and no predictive effect for pCR after conventional NACT.

Keyphrases

neoadjuvant chemotherapy
early breast cancer
locally advanced
lymph node
sentinel lymph node
electronic health record
squamous cell carcinoma
big data
early stage
machine learning
radiation therapy